Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Cash flows from operating activities:    
Net (loss) income $ (3,115) $ 798
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Stock compensation expense 507 130
Fair value adjustment of common stock warrants (3) (6)
Depreciation 10 7
Net gain on sale of intangible asset - discontinued operations 0 (2,737)
Provision for doubtful accounts and sales returns allowances - discontinued operations 0 (71)
Amortization of intangible assets 82 0
Tax benefit related to intangibles (52) 0
Loss on disposal of property and equipment 17 51
Gain on proceeds received from contingent payments - discontinued operations 0 (445)
Change in value of unconsolidated affiliate 0 501
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (93) 47
Accounts payable 50 (181)
Accrued interest on note receivable (25) 0
Accrued expenses and other liabilities (388) (37)
Current assets and liabilities from discontinued operations 177 (330)
Net cash used in operating activities (2,833) (2,273)
Cash flows from investing activities:    
Acquisition of property and equipment (90) (4)
Net proceeds received from sale of intangible asset - discontinued operations 0 2,737
Net cash received on OEM asset disposition - discontinued operations 0 502
Issuance of note receivable (300) (300)
Cash received from acquisition 476 0
Net cash provided by investing activities 86 2,935
Cash flows from financing activities:    
Net cash provided by financing activities 0 0
Effect of exchange rates on cash and cash equivalents 0 27
Net (decrease) increase in cash and cash equivalents (2,747) 689
Cash and cash equivalents at beginning of period 7,820 [1] 7,575
Cash and cash equivalents at end of period 5,073 8,264
Supplemental disclosure of non-cash activities:    
Shares issued in CollabRx acquisition 932 0
Note receivable used as consideration for CollabRx acquisition 300 0
Promissory note issued in CollabRx acquisition 500 0
Fair value of assets acquired 2,253 0
Liabilities assumed in CollabRx acquisition $ 997 $ 0
[1] Derived from the Company's audited consolidated financial statements.